Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Safety and Efficacy Assessment of Autologous Bone-marrow Derived Mesenchymal Stem Cell Therapy in Anoxic (or Hypoxic) Brain Injury.

NCT02210624 is registered in ClinicalTrials.gov with Hyun Young Kim as lead sponsor.

NCT NCT02210624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02210624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Safety and Efficacy Assessment of Autologous Bone-marrow Derived Mesenchymal Stem Cell Therapy in Anoxic (or Hypoxic) Brain Injury.
Lead sponsor
Hyun Young Kim
Phase
Not applicable
Overall status
Unknown status
Start date
March 31, 2013
Completion date
December 31, 2018
Enrollment
4 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anoxic brain injury